Antipsychotics' Hidden Threat: First 90 Days Crucial for Diabetes Risk

New research from UCL reveals a critical window in patient care: the first 90 days of antipsychotic treatment dramatically escalate the risk of diabetes and significant weight gain. The study, published today in 'The Lancet Psychiatry', shows that during this initial period, blood sugar levels (measured by HbA1c) can rise 14 times faster and body weight 9 times faster than before treatment. This finding challenges current monitoring practices, highlighting that checking weight alone isn't enough to catch dangerous metabolic changes. Patients living with severe mental illnesses like schizophrenia and bipolar disorder already face a higher risk of developing diabetes and other cardiovascular issues, often shortening their lives by 15-20 years. Antipsychotic medications, especially the newer second-generation types, are known to cause metabolic side effects, yet the precise timing and speed of these changes were less understood until now. The study found that certain drugs, like Olanzapine, can cause particularly rapid metabolic shifts, with HbA1c rising 50 times faster in the first 90 days. This quick onset underscores a significant blind spot in how patients are currently monitored. The implications are immediate for healthcare professionals, who are now advised to monitor both blood sugar and weight at the start of antipsychotic treatment and again within the first three months. This proactive approach is crucial, especially for patients with prediabetes, who are at a much higher risk of developing full-blown Type 2 diabetes. Early detection allows for timely interventions, including lifestyle changes or medication adjustments with drugs like Metformin, aiming to prevent long-term complications and improve the overall health outcomes for millions globally.